Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

September 30, 2024
alfapump® – US FDA approval anticipated Q1 2025 and US launch planned for H2 2025; Strong progress with US reimbursement – CPT III codes issued & NTAP Application filed DSR® – Publication of RED DESERT and SAHARA data in peer-reviewed “European Journal of Heart Failure” highlights potential as treatment for Cardiorenal Syndrome;  Positive data from...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES